Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Encorafenib in BRAF V600 mutation-positive Melanoma: NCT07092410 Clinical Landscape Report 2026
15 October 2026
NCT07092410 clinical landscape for BRAF V600 mutation-positive Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ciltacabtagene autoleucel in Relapse multiple myeloma: NCT07093554 Clinical Landscape Report 2026
15 October 2026
NCT07093554 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Selinexor in Acute Myeloid Leukemia: NCT07094464 Clinical Landscape Report 2026
15 October 2026
NCT07094464 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitomycin in Muscle Invasive Bladder Urothelial Carcinoma: NCT07097142 Clinical Landscape Report 2026
15 October 2026
NCT07097142 clinical landscape for Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Inobrodib in Relapse multiple myeloma: NCT07096778 Clinical Landscape Report 2026
15 October 2026
NCT07096778 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ubidecarenone in Lupus Nephritis: NCT07096557 Clinical Landscape Report 2026
15 October 2026
NCT07096557 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BN-104 in leukemia acute ambiguous lineage: NCT07101497 Clinical Landscape Report 2026
15 October 2026
NCT07101497 clinical landscape for leukemia acute ambiguous lineage: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
OriV-508 in Multiple Myeloma: NCT07101705 Clinical Landscape Report 2026
15 October 2026
NCT07101705 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ruxolitinib in Acute Myeloid Leukemia: NCT07101588 Clinical Landscape Report 2026
15 October 2026
NCT07101588 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LUCAR-DKS1 in Idiopathic Inflammatory Myopathies: NCT07095075 Clinical Landscape Report 2026
15 October 2026
NCT07095075 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Lenalidomide in Multiple Myeloma: NCT07095452 Clinical Landscape Report 2026
15 October 2026
NCT07095452 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Melanoma: NCT07099430 Clinical Landscape Report 2026
15 October 2026
NCT07099430 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.